Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999-2004)

Rebecca E. Risbon, L. P. De Lorimier, Katherine A Skorupski, K. E. Burgess, P. J. Bergman, J. Carreras, K. Hahn, A. LeBlanc, M. Turek, J. Impellizeri, R. Fred, J. W. Wojcieszyn, K. Drobatz, C. A. Clifford

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background: Epitheliotropic lymphoma (ELSA) is an uncommon cutaneous canine malignancy of T lymphocytes. A consensus regarding the therapeutic standard of care is lacking, warranting evaluation of chemotherapeutic agents traditionally employed against canine nodal lymphoma in the treatment of ELSA. Hypothesis: The purpose of this retrospective, multi-institutional study was to evaluate the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of ELSA. Animals: Forty-six dogs with adequate follow-up and treatment response information. Methods: All cases were diagnosed histopathologically. Immunohistochemisty (CD3, CD79a) was performed on 42/46 samples. Results: Presenting skin lesions included generalized scales (25/46), plaques or nodules (22/46), mucocutaneous lesions (14/ 46), and corneal involvement (1/46). Lymph node involvement and Sézary syndrome were documented in 7 and 2 dogs, respectively. The median number of CCNU treatments was 4 (range, 1-11), with a median starting dose of 60 mg/m2 (range, 30-95). Of the 46 dogs, 15 achieved complete remission, 23 achieved partial remission, 5 had stable disease, and 3 had progressive disease, for an overall response rate of 83%. The median number of treatments to achieve a response was 1 (range, 1-6). The overall median duration of response was 94 days (range, 22-282). Sixteen dose reductions were required because of neutropenia (10/46), thrombocytopenia (1/46), anemia (1/46), increased liver enzyme activity (3/46), or unspecified reasons (1/46). Conclusions and Clinical Implications: Given the high response rate and well tolerated protocol, prospective studies are warranted to investigate the utility of CCNU alone or in multi-agent protocols for the treatment of ELSA.

Original languageEnglish (US)
Pages (from-to)1389-1397
Number of pages9
JournalJournal of Veterinary Internal Medicine
Volume20
Issue number6
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

mycosis fungoides
Lomustine
retrospective studies
Canidae
Lymphoma
Retrospective Studies
Skin
dogs
remission
Dogs
Therapeutics
neutropenia
thrombocytopenia
skin lesions
dosage
lymphoma
prospective studies
lesions (animal)
anemia
lymph nodes

Keywords

  • Alkylator
  • Chemotherapy
  • Epitheliotropic lymphoma
  • Mycosis fungoides
  • Nitrosourea
  • Skin

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU) : A retrospective study of 46 cases (1999-2004). / Risbon, Rebecca E.; De Lorimier, L. P.; Skorupski, Katherine A; Burgess, K. E.; Bergman, P. J.; Carreras, J.; Hahn, K.; LeBlanc, A.; Turek, M.; Impellizeri, J.; Fred, R.; Wojcieszyn, J. W.; Drobatz, K.; Clifford, C. A.

In: Journal of Veterinary Internal Medicine, Vol. 20, No. 6, 11.2006, p. 1389-1397.

Research output: Contribution to journalArticle

Risbon, RE, De Lorimier, LP, Skorupski, KA, Burgess, KE, Bergman, PJ, Carreras, J, Hahn, K, LeBlanc, A, Turek, M, Impellizeri, J, Fred, R, Wojcieszyn, JW, Drobatz, K & Clifford, CA 2006, 'Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999-2004)', Journal of Veterinary Internal Medicine, vol. 20, no. 6, pp. 1389-1397. https://doi.org/10.1892/0891-6640(2006)20[1389:ROCCEL]2.0.CO;2
Risbon, Rebecca E. ; De Lorimier, L. P. ; Skorupski, Katherine A ; Burgess, K. E. ; Bergman, P. J. ; Carreras, J. ; Hahn, K. ; LeBlanc, A. ; Turek, M. ; Impellizeri, J. ; Fred, R. ; Wojcieszyn, J. W. ; Drobatz, K. ; Clifford, C. A. / Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU) : A retrospective study of 46 cases (1999-2004). In: Journal of Veterinary Internal Medicine. 2006 ; Vol. 20, No. 6. pp. 1389-1397.
@article{d3af5ca1aafe40ad8efc4de3d2a2964a,
title = "Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999-2004)",
abstract = "Background: Epitheliotropic lymphoma (ELSA) is an uncommon cutaneous canine malignancy of T lymphocytes. A consensus regarding the therapeutic standard of care is lacking, warranting evaluation of chemotherapeutic agents traditionally employed against canine nodal lymphoma in the treatment of ELSA. Hypothesis: The purpose of this retrospective, multi-institutional study was to evaluate the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of ELSA. Animals: Forty-six dogs with adequate follow-up and treatment response information. Methods: All cases were diagnosed histopathologically. Immunohistochemisty (CD3, CD79a) was performed on 42/46 samples. Results: Presenting skin lesions included generalized scales (25/46), plaques or nodules (22/46), mucocutaneous lesions (14/ 46), and corneal involvement (1/46). Lymph node involvement and S{\'e}zary syndrome were documented in 7 and 2 dogs, respectively. The median number of CCNU treatments was 4 (range, 1-11), with a median starting dose of 60 mg/m2 (range, 30-95). Of the 46 dogs, 15 achieved complete remission, 23 achieved partial remission, 5 had stable disease, and 3 had progressive disease, for an overall response rate of 83{\%}. The median number of treatments to achieve a response was 1 (range, 1-6). The overall median duration of response was 94 days (range, 22-282). Sixteen dose reductions were required because of neutropenia (10/46), thrombocytopenia (1/46), anemia (1/46), increased liver enzyme activity (3/46), or unspecified reasons (1/46). Conclusions and Clinical Implications: Given the high response rate and well tolerated protocol, prospective studies are warranted to investigate the utility of CCNU alone or in multi-agent protocols for the treatment of ELSA.",
keywords = "Alkylator, Chemotherapy, Epitheliotropic lymphoma, Mycosis fungoides, Nitrosourea, Skin",
author = "Risbon, {Rebecca E.} and {De Lorimier}, {L. P.} and Skorupski, {Katherine A} and Burgess, {K. E.} and Bergman, {P. J.} and J. Carreras and K. Hahn and A. LeBlanc and M. Turek and J. Impellizeri and R. Fred and Wojcieszyn, {J. W.} and K. Drobatz and Clifford, {C. A.}",
year = "2006",
month = "11",
doi = "10.1892/0891-6640(2006)20[1389:ROCCEL]2.0.CO;2",
language = "English (US)",
volume = "20",
pages = "1389--1397",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU)

T2 - A retrospective study of 46 cases (1999-2004)

AU - Risbon, Rebecca E.

AU - De Lorimier, L. P.

AU - Skorupski, Katherine A

AU - Burgess, K. E.

AU - Bergman, P. J.

AU - Carreras, J.

AU - Hahn, K.

AU - LeBlanc, A.

AU - Turek, M.

AU - Impellizeri, J.

AU - Fred, R.

AU - Wojcieszyn, J. W.

AU - Drobatz, K.

AU - Clifford, C. A.

PY - 2006/11

Y1 - 2006/11

N2 - Background: Epitheliotropic lymphoma (ELSA) is an uncommon cutaneous canine malignancy of T lymphocytes. A consensus regarding the therapeutic standard of care is lacking, warranting evaluation of chemotherapeutic agents traditionally employed against canine nodal lymphoma in the treatment of ELSA. Hypothesis: The purpose of this retrospective, multi-institutional study was to evaluate the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of ELSA. Animals: Forty-six dogs with adequate follow-up and treatment response information. Methods: All cases were diagnosed histopathologically. Immunohistochemisty (CD3, CD79a) was performed on 42/46 samples. Results: Presenting skin lesions included generalized scales (25/46), plaques or nodules (22/46), mucocutaneous lesions (14/ 46), and corneal involvement (1/46). Lymph node involvement and Sézary syndrome were documented in 7 and 2 dogs, respectively. The median number of CCNU treatments was 4 (range, 1-11), with a median starting dose of 60 mg/m2 (range, 30-95). Of the 46 dogs, 15 achieved complete remission, 23 achieved partial remission, 5 had stable disease, and 3 had progressive disease, for an overall response rate of 83%. The median number of treatments to achieve a response was 1 (range, 1-6). The overall median duration of response was 94 days (range, 22-282). Sixteen dose reductions were required because of neutropenia (10/46), thrombocytopenia (1/46), anemia (1/46), increased liver enzyme activity (3/46), or unspecified reasons (1/46). Conclusions and Clinical Implications: Given the high response rate and well tolerated protocol, prospective studies are warranted to investigate the utility of CCNU alone or in multi-agent protocols for the treatment of ELSA.

AB - Background: Epitheliotropic lymphoma (ELSA) is an uncommon cutaneous canine malignancy of T lymphocytes. A consensus regarding the therapeutic standard of care is lacking, warranting evaluation of chemotherapeutic agents traditionally employed against canine nodal lymphoma in the treatment of ELSA. Hypothesis: The purpose of this retrospective, multi-institutional study was to evaluate the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of ELSA. Animals: Forty-six dogs with adequate follow-up and treatment response information. Methods: All cases were diagnosed histopathologically. Immunohistochemisty (CD3, CD79a) was performed on 42/46 samples. Results: Presenting skin lesions included generalized scales (25/46), plaques or nodules (22/46), mucocutaneous lesions (14/ 46), and corneal involvement (1/46). Lymph node involvement and Sézary syndrome were documented in 7 and 2 dogs, respectively. The median number of CCNU treatments was 4 (range, 1-11), with a median starting dose of 60 mg/m2 (range, 30-95). Of the 46 dogs, 15 achieved complete remission, 23 achieved partial remission, 5 had stable disease, and 3 had progressive disease, for an overall response rate of 83%. The median number of treatments to achieve a response was 1 (range, 1-6). The overall median duration of response was 94 days (range, 22-282). Sixteen dose reductions were required because of neutropenia (10/46), thrombocytopenia (1/46), anemia (1/46), increased liver enzyme activity (3/46), or unspecified reasons (1/46). Conclusions and Clinical Implications: Given the high response rate and well tolerated protocol, prospective studies are warranted to investigate the utility of CCNU alone or in multi-agent protocols for the treatment of ELSA.

KW - Alkylator

KW - Chemotherapy

KW - Epitheliotropic lymphoma

KW - Mycosis fungoides

KW - Nitrosourea

KW - Skin

UR - http://www.scopus.com/inward/record.url?scp=33845693997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845693997&partnerID=8YFLogxK

U2 - 10.1892/0891-6640(2006)20[1389:ROCCEL]2.0.CO;2

DO - 10.1892/0891-6640(2006)20[1389:ROCCEL]2.0.CO;2

M3 - Article

C2 - 17186855

AN - SCOPUS:33845693997

VL - 20

SP - 1389

EP - 1397

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 6

ER -